A place to learn about building a new type of biotech that aims to better serve patients.

Videos, white papers, resources & opinions

White Paper & Video · 2026 · PDF

Genetic Targets, Financial Creativity

BridgeBio’s model for sustainable drug development
Biotech drug development is a high-risk, capital-intensive endeavor, requiring a balance between scientific advancement and financial creativity.
Read more

Latest Ideas

White Paper · 2025 · PDF

Unlocking the feasibility of rare disease drug development

Millions of people are affected by rare diseases worldwide, yet fewer than 10% have approved treatments. This is largely because the high cost of drug development makes developing medicines infeasible for diseases with small patient populations.

Opinion · 2026

What makes a drug launch successful?

Having been fortunate to bring multiple medicines to market across several therapeutic areas, I have realized that the success of a launch is rarely attributed to one factor.

Podcast · May 2026

Neil Kumar on the Off-Target Effects podcast

Neil reflects on what it takes to serve patients well, build enduring capabilities, and create a sustainable biotech business in areas where others have historically been less focused.

Opinion & Video · May 2026

Scaling Innovation for Rare Diseases

Our CEO, Neil Kumar joined a panel moderated by CNBC Cure's Becky Quick to discuss how rewriting the rules will facilitate more rapid, cost-efficient, and scalable progress for the global rare disease community.

Opinion · Sep 2026

The Genetic Testing Gap

The symptoms can look very different, but for many patients they trace back to the same overlooked cause: a rare genetic disease that hasn’t yet been named.

Opinion · Sep 2026

Opening a Door in D.C., Closing the Gap for Patients

The door is open. We invite advocates, people living with rare conditions, regulators, policymakers, researchers, and others working across the rare disease community to engage with us in this space, challenge us, and help us move with greater urgency.